CATAFLU.OR

OrganoCATAlytic approaches towards easily synthesized ,economical and high yielding Tamiflu derivatives

Unibo Team Leader: Prof. Pier Giorgio Cozzi, Dip. di Chimica "G.Ciamician"

Despite widespread immunization, influenza still kills thousand of people, and costs to US, Europe and Asia enormous amount of money in term of healthcare expenses and productivity losses. While immunization remains an important approach to prevent influenza, small-molecule antiviral agents represent a novel opportunity for effective prevention and therapy of flu.
Inhibitors of neuraminidase, essential enzyme for viral replication in all three classes of influenza viruses, have been recently found.
Two of these inhibitors have reached the market, namely, zanamivir (GSKBs Relenza (1)) in July 1999, and oseltamivir phosphate (Gilead Bs Tamiflu (2), also marketed by Roche) in October 1999.
The recent healthy problem related to avian flu, has increase the public demand for stockpiles of Tamiflu, both as a reasonable frontline therapy against a possible flu pandemic and as a preventive agent. However, natural sources of drug (Shikimic acid) are scarcely, and increasing demand for oseltamivir phosphate has placed further pressure on Roche and the chemical community in general to develop new routes to the drug that do not involve complex natural products. In addition, the described synthesis are expensive and difficult. Moreover, in this synthesis, use of hazardous azide-based reagents was necessary.
New routes of Tamiflu have been recently described, but more than 12 steps in one case and 17 in another are needed. In order to find new drug candidates, cut the drug costs and improving availability as well as efficiency, new chemical synthesis are necessary. We propose a new domino reaction based on an organocatalytic approach to the synthesis of new Tamiflu derivatives. The chemistry involved in this project is easy to perform, and well adapt to industrial contest. Moreover, new chemical structures will be prepared and evaluated as potential drug against virulent and mutated flu viruses.

Coordinator
Prof. Pier Giorgio Cozzi, Dip. di Chimica "G.Ciamician"
ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA
Other participants

  • UNIVERSITAET ZU KOELN (Germany)
  • HONG KONG POLYTECHNIC UNIVERSITY (China)
  • HELSINGIN YLIOPISTO (Finlandia)
  • UNIVERZITA KOMENSKEHO V BRATISLAVE (Slovacchia)
  • SYNKOLA, S.R.O. (Slovacchia)
  • SUN YAT-SEN UNIVERSITY (China)

 

Start date 01/04/2008

End date 31/03/2011

Duration 36 mesi

Project cost 2965217 Euro

Project Funding 2300000 Euro

Subprogramme Area Influenza research in collaboration with Asian partners

Contract type SICA